ABHD17B: A Potential Drug Target and Biomarker (G51104)

Target Name: ABHD17B

NCBI ID: G51104

ABHD17B

ABHD17B: A Potential Drug Target and Biomarker

Introduction

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder that affects the kidney function, leading to the need for lifelong kidney replacement therapy. The majority of patients with ADPKD have one copy of an abnormal gene, ABHD17B, which encodes a protein involved in the regulation of water and electrolyte balance in the kidney. The severity of ADPKD is often determined by the number of cysts present in the kidneys. cysts can cause kidney function impairment, leading to symptoms such as proteinuria, hematuria, and decreased kidney size.

The discovery of ABHD17B as a potential drug target and biomarker has significant implications for the treatment of ADPKD. By targeting this gene, researchers hope to develop new therapies that can slow the progression of the disease and improve kidney function in patients.

The Structure of ABHD17B

ABHD17B is a member of the B1 family of proteins, which are known for their role in regulating water and electrolyte balance in various biological systems. The B1 family consists of six structurally similar genes: ABHD17A, ABHD17B, ABHD17C, ABHD17D, ABHD17E, and ABHD17F . These genes differ in their last exon, which is used to create a distinct protein.

ABHD17B is a 138- amino acid protein that contains a unique N-terminus and a C-terminus. The N-terminus of ABHD17B contains a putative transmembrane domain, which is involved in the formation of a protein-protein interaction network. The C- The terminus of ABHD17B contains a unique N-terminal domain that is involved in the regulation of protein stability and localization.

Expression and knockdown of ABHD17B

ABHD17B is expressed in a variety of tissues and cells, including kidney, heart, and brain. It is primarily expressed in the kidney, where it is involved in the regulation of water and electrolyte balance. ABHD17B is also expressed in other tissues, such as heart and brain, where it may have other functions.

To study the expression of ABHD17B, researchers have used RNA interference (RNAi) to knockdown the gene in various cell types. They have found that ABHD17B is highly expressed in the kidney, and that it is involved in the regulation of water and electrolyte balance.

Drug Targeting of ABHD17B

The potential drug targeting of ABHD17B is based on its involvement in the regulation of water and electrolyte balance in the kidney. Drugs that can interfere with the function of ABHD17B, such as diuretics or renin inhibitors, may be effective in slowing the progression of ADPKD.

In addition to drugs that directly target ABHD17B, researchers are also exploring the use of small molecules that can interact with its unique N-terminus. This approach may be more effective than directly targeting the protein itself, as drugs can be used to modulate its activity without affecting its structure.

Biomarker Development

The discovery of ABHD17B as a potential drug target and biomarker has significant implications for the diagnosis and treatment of ADPKD. By using techniques such as RNA interference and drug screening, researchers have been able to identify potential small molecules that can interact with ABHD17B and slow the progression of the disease.

In addition to its potential as a drug target, ABHD17B also has potential as a biomarker. The regulation of water and electrolyte balance is a critical aspect of kidney function, and changes in this regulation can be indicative of underlying kidney disease. By measuring the expression of ABHD17B in various tissues and cells, researchers have been able to determine

Protein Name: Abhydrolase Domain Containing 17B, Depalmitoylase

Functions: Hydrolyzes fatty acids from S-acylated cysteine residues in proteins (PubMed:26701913). Has depalmitoylating activity towards DLG4/PSD95 (PubMed:26701913). Has depalmitoylating activity towards GAP43 (By similarity). Has depalmitoylating activity towards MAP6 (By similarity). Has depalmitoylating activity towards NRAS (PubMed:26701913)

The "ABHD17B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ABHD17B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets